(a) RequestA person who submits an application or submission (including a petition, notification, and any other similar form of request) under this chapter for a product, may submit a request to the Secretary respecting the classification of the product as a drug, biological product, device, or a combination product subject to section 353(g) of this title or respecting the component of the Food and Drug Administration that will regulate the product. In submitting the request, the person shall recommend a classification for the product, or a component to regulate the product, as appropriate.
(b) StatementNot later than 60 days after the receipt of the request described in subsection (a), the Secretary shall determine the classification of the product under subsection (a), or the component of the Food and Drug Administration that will regulate the product, and shall provide to the person a written statement that identifies such classification or such component, and the reasons for such determination. The Secretary may not modify such statement except with the written consent of the person, or for public health reasons based on scientific evidence.
(c) Inaction of SecretaryIf the Secretary does not provide the statement within the 60-day period described in subsection (b), the recommendation made by the person under subsection (a) shall be considered to be a final determination by the Secretary of such classification of the product, or the component of the Food and Drug Administration that will regulate the product, as applicable, and may not be modified by the Secretary except with the written consent of the person, or for public health reasons based on scientific evidence.
Structure US Code
CHAPTER 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT
SUBCHAPTER V— DRUGS AND DEVICES
Part E— General Provisions Relating to Drugs and Devices
§ 360bbb. Expanded access to unapproved therapies and diagnostics
§ 360bbb–0. Expanded access policy required for investigational drugs
§ 360bbb–0a. Investigational drugs for use by eligible patients
§ 360bbb–1. Dispute resolution
§ 360bbb–2. Classification of products
§ 360bbb–3. Authorization for medical products for use in emergencies
§ 360bbb–3a. Emergency use of medical products
§ 360bbb–3b. Products held for emergency use
§ 360bbb–3c. Expedited development and review of medical products for emergency uses
§ 360bbb–4. Countermeasure development, review, and technical assistance
§ 360bbb–4b. Medical countermeasure master files
§ 360bbb–5. Critical Path Public-Private Partnerships
§ 360bbb–5a. Emerging technology program
§ 360bbb–6. Risk communication
§ 360bbb–8a. Optimizing global clinical trials
§ 360bbb–8b. Use of clinical investigation data from outside the United States
§ 360bbb–8c. Patient participation in medical product discussion
§ 360bbb–8d. Notification, nondistribution, and recall of controlled substances